Wizenius

JULY 2, 2023

PE firms collaborate with the management teams of their invested companies, pooling industry expertise with financial prowess. For instance, when a fast-growing e-commerce player like Shopify reaches its peak, an exit via an Initial Public Offering (IPO) can yield substantial profits.

Private Equity 52

Private Equity Equities Investment Financial Modeling 52

Sun Acquisitions

SEPTEMBER 16, 2024

Enhance your business’s attractiveness to potential buyers by focusing on key value drivers such as revenue growth, profitability, customer retention, intellectual property, and operational efficiency. Invest in strategic initiatives to boost your company’s performance and market position, ultimately increasing its valuation.

Negotiation 59

Negotiation Business Sale Management 59

Focus Investment Banking

FEBRUARY 25, 2024

I still recall the metric that was drilled into me back then: hit $50 million in revenue and a few back-to-back years of profitability and you, too, can go public. The benefits of going public are significant. This contrasts with the rigid timelines and standardized processes associated with IPOs.

Private Equity 52

Private Equity IPO Equities Public Trading 52

Peak Frameworks

OCTOBER 30, 2023

Morgan, which offer services in underwriting and M&A advisory. The profit-making strategies differ across these banks. Subtracting the $50 paid to you, the bank makes a net profit of $350. This increased activity translates to more commissions for banks and potentially higher profits from proprietary trading.

Bank 52

Bank Banking Proprietary Trading Investment Banking 52

Cooley M&A

JANUARY 25, 2023

Although there were 104 initial public offerings of biotechnology companies in 2021 that raised nearly $15 billion in funds, 2022 saw only 22 such IPOs collectively raising less than $2 billion. Let’s dig in. Buyers appeared more willing to take on risk in licensing partnerships than in traditional M&A.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 23, 2024

Collaborate or buy?’ question remains key Buyers in the life sciences industry continue to face the decision of whether to acquire a company or enter into a collaboration deal, which is influenced by the potential benefits of the partnership, the risks of only partial control, the ability to align on upfront valuation and antitrust risk.

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52